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Abstract
Introduction The cell-cycle checkpoint kinase (CHEK)2 protein
truncating mutation 1100delC has been associated with
increased risk for breast or prostate cancer. Multiple studies
have found an elevated frequency of the 1100delC variant in
specific stratifications of breast cancer patients with a family
history of the disease, including BRCA1/BRCA2  negative
families and families with a history of bilateral disease or male
breast cancer. However, the 1100delC mutation has only been
investigated in a few population-based studies and none from
North America.
Methods We report here on the frequency of three CHEK2
variants that alter protein function – 1100delC, R145W, and
I175T – in 506 cases and 459 controls from a population
based, case–control study of breast cancer conducted in young
women from western Washington.
Results There was a suggestive enrichment in the 1100delC
variant in the cases (1.2%) as compared with the controls
(0.4%), but this was based on small numbers of carriers and the
differences were not statistically significant. The 1100delC
variant was more frequent in cases with a first-degree family
history of breast cancer (4.3%; P = 0.02) and slightly enriched
in cases with a family history of ovarian cancer (4.4%; P = 0.09).
Conclusion The CHEK2  variants are rare in the western
Washington population and, based on accumulated evidence
across studies, are unlikely to be major breast cancer
susceptibility genes. Thus, screening for the 1100delC variant
may have limited usefulness in breast cancer prevention
programs in the USA.
Keywords: breast cancer, case–control study, CHEK2, population based
Introduction
Cell-cycle checkpoint kinase (CHEK)2 has been shown to
play a role in cell cycle regulation, apoptosis, and DNA
repair, at least in part through phosphorylation of p53 and
BRCA1 in response to DNA damage [1,2]. Several studies
have reported associations of germline mutations in
CHEK2, especially the 1100delC mutation, with increased
susceptibility to breast and prostate cancer [3-8]. Although
CHEK2 germline variants other than 1100delC have been
associated with prostate cancer risk, these have not yet
been shown to be enriched in breast cancer cases
[3,4,9,10].
The association between the CHEK2  1100delC variant
and risk for breast cancer was initially reported by the
CHEK2 Breast Cancer Consortium [5]. They found that the
frequency of the variant was greater among breast cancer
patients with a positive family history of breast cancer who
do not carry germline mutations in the BRCA1 or BRCA2
genes, and in families with male breast cancer, as com-
pared with healthy control individuals from the UK, The
Netherlands, and North America [5]. Additionally, they
noted that the frequency of the 1100delC variant did not
differ significantly between breast cancer patients and
matched control individuals from a population-based series
of young women from the UK (age < 45 years) and of older
women from The Netherlands (age ≥ 55 years) [5].
bp = base pairs; CHEK = cell-cycle checkpoint kinase; PCR = polymerase chain reaction.Breast Cancer Research    Vol 6 No 6    Friedrichsen et al.
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However, neither population-based series included fre-
quency data after stratifying for family history
characteristics.
Several additional studies have addressed the association
of the 1100delC variant and breast cancer risk in unique
populations. In a Finnish study conducted by Vahteristo
and coworkers [6], the frequency of the 1100delC muta-
tion was observed to be slightly but not significantly higher
in an unselected cohort of breast cancer patients than in
control individuals (identified from the Finnish Red Cross
Blood Service). Significant enrichment of the variant was
found among index cases with a first-degree or second-
degree relative with breast or ovarian cancer, and in women
with bilateral breast cancer as compared with patients with
unilateral disease. Finally, analysis of the variant in a set of
patients with positive family history who were not BRCA1
or BRCA2 germline mutation carriers demonstrated a sig-
nificantly elevated frequency of the 1100delC variant as
compared with controls. These findings from Vahteristo
and coworkers [6] and recent work from Oldenburg and
colleagues [7] are similar to data from the CHEK2 Breast
Cancer Consortium, and suggest a significant role played
by the 1100delC variant in breast cancer among women
with a positive family history of breast cancer whose dis-
ease is not attributable to germline mutations in BRCA1 or
BRCA2.
Finally, a study from New York by Offit and coworkers [8]
reported a lower frequency of 1100delC carriers in both
breast cancer cases and controls as compared with previ-
ous studies that largely included Northern European indi-
viduals. The 1100delC mutation was identified in 1.0% of
cases, which was not statistically different (P = 0.10) from
that observed among controls (0.3%), who were volunteers
from the New York Cancer Project. Compared with the
general population frequency in New York, the 1100delC
variant appears to be even rarer among breast cancer
patients from Spain [11] and India [12], where studies to
date have reported no individuals with the 1100delC
variant.
To understand better the association of CHEK2 variants
and breast cancer risk in the general population in the USA,
we analyzed the frequency of three CHEK2  variants –
1100delC, R145W, and I175T, each of which reportedly
alters CHEK2 protein function – in a population based,
case–control study of 506 breast cancer cases diagnosed
before age 45 years from western Washington state, and a
set of 459 frequency matched control individuals.
Methods
Study population
A characterization of the study population has previously
been reported and is summarized only briefly [13,14].
Cases were identified through the Cancer Surveillance
System of Western Washington, a population-based can-
cer registry and a participant in the National Cancer Insti-
tute's Surveillance, Epidemiology, and End Results
Program (SEER). Control individuals were identified
through random digit dialing and were frequency matched
to the cases on 5-year age group and reference year [15].
The study identified all incident first primary breast cancer
cases diagnosed before age 45 years, from May 1 1990 to
December 31 1992, in women of all races and ethnic back-
grounds, who were residents of King, Pierce and Snohom-
ish counties at the time of diagnosis. Information on
potential risk factors for breast cancer, including family his-
tory, was obtained through a structured in-person interview.
The reference date for the interview, a date beyond which
exposure information was not collected, was the month and
year of diagnosis for cases and a randomly assigned date
for controls. Interviews were completed for 642 cases
(84.0%) and 608 controls (73.8% overall response rate).
Blood was collected from 540 interviewed cases and 476
interviewed controls.
Tested cases tended to be older than untested cases from
the study (P = 0.001) whereas no such age-related differ-
ences were seen in controls. Untested cases were more
likely to have advanced stage disease (51.0% of tested and
41.2% of untested cases had local stage disease, 30.2%
and 40.4% had regional disease, and 1.4% and 5.9% had
distant disease; P = 0.001) and were more likely to be
deceased at the last follow up in June 2002 (16.6% of
tested and 48.8% of untested cases were deceased; P <
0.001). For 40% of participants, blood collection was not
attempted until after the initial interview, probably account-
ing in part for these differences. We observed no difference
in cases or controls between those tested and untested
with regard to family history.
Molecular methods
Batches of DNA for genotyping were constructed to con-
tain both case and control samples, and genotyping per-
sonnel were blinded as to the case–control status of
samples. Previously described specific primers for CHEK2
exon 10 were used for PCR amplification [16]: 5'-TTA ATT
TAA GCA AAA TTA AAT GTC-3' and 5'-GGC ATG GTG
GTG TGC ATC-3'. Genomic DNA (25 ng) was amplified
using the AccuPrime TAQ DNA polymerase system (Invit-
rogen, Carlsbad, CA, USA). Touchdown PCR conditions
for the 1100delC amplicon were as follows: denaturation at
94°C for 1 min then 94°C for 30 s, 60°C for 30 s, and 68°C
for 30 s for seven cycles with the annealing temperature
decreasing by 1°C for each cycle, followed by an additional
28 cycles of 94°C for 30 s, 54°C for 30 s, and 68°C for 30
s. The resulting 556 bp amplicon was analyzed by unidirec-
tional DNA sequencing with the reverse primer. The
R145W and I175T variants were sequenced from a 409Available online http://breast-cancer-research.com/content/6/6/R629
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bp amplicon generated using the following primers: 5'-TTG
CCT TCT TAG GCT ATT TTC C-3' and 5'-AAA GGT TCC
ATT GCC ACT GT-3'. As above, 25 ng genomic DNA with
AccuPrime TAQ DNA polymerase was amplified by touch-
down PCR, in which the starting annealing temperature
was 64°C and the final annealing temperature was 58°C.
For sequencing, the Applied Biosystems Big Dye Termina-
tor Ready Reaction Mix (Foster City, CA, USA) was used in
accordance with the manufacturer's recommended
protocol.
Genotyping was conducted in 506 cases and 459 con-
trols. Valid results for all participants were obtained for the
R145W and I175T variants, whereas results for one case
and one control were not obtained for the 1100delC
variant.
Analysis
To assess the relationship between CHEK2 variants and
breast cancer risk, logistic regression was used to obtain
odds ratios as estimates of the relative risk and 95% confi-
dence intervals [17]. All analyses were completed using
Stata statistical software (StataCorp LP, College Station,
TX, USA).
Because reference age and year were matching variables
for the frequency matching employed in the original study,
all risk estimates presented are age (continuous)-and refer-
ence year (exact)-adjusted.
A subset of the samples analyzed in the study had been
screened previously for germline mutations in the breast
cancer susceptibility genes BRCA1 and BRCA2 [18,19].
Cases were selected for BRCA1/BRCA2 screening on the
basis of an age of diagnosis under 35 years and/or a first-
degree family history of breast cancer (n = 134). In addi-
tion, 235 controls were tested for mutations in the BRCA1
gene, and 37 of these controls were additionally tested for
BRCA2. Overall, 110 cases and 33 controls were available
for consideration of CHEK2 variant frequencies in BRCA1/
BRCA2 mutation negative subjects.
Results
Study population characteristics
Tested cases and controls were generally similar with
regard to age, menopausal status, and racial distribution
(Table 1). Approximately 90% of all participants were Cau-
casian. Cases more often reported a family history of breast
cancer than did controls, particularly a first-degree family
history, which was reported by 19.0% of cases and 8.1%
of controls.
Table 1
Characteristics of cases and controls
Characteristic Cases (n = 506) Controls (n = 459)
n % n %
Age at reference (years)
< 35 62 12.3 80 17.4
35+ 444 87.7 379 82.6
Race
White 450 88.9 412 89.8
Nonwhite 56 11.1 47 10.2
Family history
None 280 56.7 294 66.1
First degree 94 19.0 36 8.1
Second degree 120 24.3 115 25.8
Unknown 12 14
Menopausal status
Premenopausal 445 88.3 392 85.8
Postmenopausal 59 11.7 65 14.2
Unknown 2 2Breast Cancer Research    Vol 6 No 6    Friedrichsen et al.
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Variants and risk for breast cancer
Overall, no statistically significant differences were
observed in frequency between cases and controls for any
of the three variants tested (Table 2) and all three variants
studied were uncommon. For the 1100delC mutation, a
2.9-fold increased risk was observed among cases com-
pared with controls, because six (1.2%) out of 505 cases
and two (0.4%) out of 458 controls carried the variant.
However, the confidence interval did not exclude 1 and
thus chance cannot be excluded as an explanation (95%
confidence interval 0.6–14.6).
We examined the frequencies of the CHEK2  variants
according to age, race, and family history features of the
probands (Table 3). All 1100delC deletion carriers were
Caucasian. Among the cases, 0.7% (2/280) of those with
no family history of breast cancer, none (0/120) with only a
second-degree family history, and 4.3% (4/94) of those
with a first-degree family history were found to carry the
1100delC variant (P = 0.02). Among controls, 0.3% (1/
294) of those with no family history, 0.9% (1/115) of those
with only a second-degree family history, and none (0/36)
of the controls with a first-degree family history carried the
1100delC variant.
One case, or 2.4% of those with a family history of bilateral
breast cancer, and one control, or 3.2% of those with a sim-
ilar family history, were carriers. Cases with a positive first-
degree or second-degree family history of ovarian cancer
carried an 1100delC variant more frequently (4.4% [2/45])
than did cases with no such family history (0.9% [4/461];
P = 0.09). No controls (0/27) with such family history were
carriers. Furthermore, 9.1% (2/22) of the cases with a pos-
itive family history of both breast and ovarian cancer were
found to carry the 1100delC variant (P = 0.07). In the over-
all dataset, only three cases and two controls reported a
family history of male breast cancer, and none carried the
1100delC variant.
The R145W variant was rare in this data set, with only one
case and no controls carrying the variant (Table 2). The car-
rier case was diagnosed before age 30 years, was Cauca-
sian, and reported one first-degree relative with breast
cancer who was diagnosed after age 45 years and no fam-
ily history of ovarian cancer, bilateral breast cancer, or male
breast cancer (data not shown).
The I175T change was observed in two (0.4%) of 506
cases and four (0.9%) of 459 controls (odds ratio 0.5, 95%
confidence interval 0.1–2.6; Table 2). One control carrier
was non-Caucasian. One case (0.4%) and three controls
(1.0%) with no family history of breast cancer carried the
I175T change. The other case carrying this variant was in
the group with a first-degree family history of breast cancer
(1/94 [1.1%]) and the other control carrying this variant
was among controls with a second-degree family history
(1/115 [0.9%]). None of the I175T carriers had a family his-
tory of ovarian cancer, bilateral breast cancer, or male
breast cancer.
Non-BRCA1/BRCA2 carriers and CHEK2 mutations
Because some studies suggest that the CHEK2 1100delC
variant acts as a breast cancer modifier in non-BRCA1/
BRCA2 families only [5-7], we considered the subset of
women known not to be BRCA1 or BRCA2 germline muta-
tion carriers. Within this subset of 110 cases and 33 con-
trols, four (3.6%) cases and no (0%) controls carried the
1100delC variant (P = 0.27), one case and no controls car-
ried the R145W change, and one case and no controls car-
ried the I175T change. No CHEK2 variants were observed
in any known BRCA1 or BRCA2 mutation carrier.
Discussion
We analyzed three CHEK2 variants that are known to dis-
rupt protein function (1100delC, R145W, and I175T) in a
population based, case–control study of breast cancer
among young North American women. The 1100delC vari-
ant is a protein truncating mutation that abrogates CHEK2
kinase activity [20]. R145W has been shown to have dis-
rupted kinase activity [20,21] and I175T is deficient in bind-
ing and phosphorylation of Cdc25A and in binding to
BRCA1 and p53 [20-22]. Although an enrichment in the
1100delC variant and a reduction in I175T carriers in the
cases were noted, no statistically significant association
between any of the CHEK2 variants and breast cancer risk
was observed. The absolute number of participants carry-
ing CHEK2 variants was relatively small, and thus there
was limited power to examine frequencies according to
family history features. Nonetheless, among cases there
was some suggestion that the 1100delC variant may be
slightly more frequent in those with a positive first-degree
family history of breast cancer (P = 0.02) and in those with
any family history of ovarian cancer (P = 0.09). However, in
agreement with two other breast cancer studies [9,10], we
observed no suggestive correlation between the R145W
and I175T CHEK2  variants and breast cancer risk. No
CHEK2 variants were seen among women found previ-
ously to carry a BRCA1/BRCA2 mutation.
Our overall frequency results for 1100delC of 1.2% for
cases and 0.4% for controls are similar to the frequencies
reported previously from the UK, Philadelphia, and New
York [5,6,8]. In a population based series of individuals
from the UK and The Netherlands, the frequency of the
1100delC variant was higher among cases, but did not dif-
fer significantly from a set of matched controls (1.3% and
2.5% for cases and 0.3% and 1.2% for controls, respec-
tively) [5]. Likewise, the frequency of 1100delC in a Finnish
series of breast cancer patients was similar to that reported
among control individuals from the Finnish Red CrossAvailable online http://breast-cancer-research.com/content/6/6/R629
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Blood Transfusion Service (2.0% and 1.4%, respectively; P
= 0.18) [6]. Finally, in North America the 1100delC variant
was identified in 1.6% of index cases from breast cancer
families in Philadelphia and in 0.6% of control individuals
(from the same neighborhood or spouses marrying into a
breast cancer family from the same area) [5]. In New York
examination of the 1100delC variant in 192 women with a
family history of breast cancer, 92 women with a personal
history of breast cancer, and 16 male breast cancer
patients [8] revealed a mutation frequency of 1.0%, which
did not differ significantly from the frequency of 0.3% found
in volunteers for the New York Cancer Project (P = 0.10).
Several previously published studies [5-7,23] reported an
elevated frequency of the CHEK2 1100delC variant in spe-
cific stratifications of breast cancer patients. Specifically,
individuals with positive family history (especially those who
are BRCA1/BRCA2 mutation negative), patients with bilat-
eral disease, and patients with a family history of male
breast cancer had a higher occurrence of 1100delC vari-
ants as compared with control individuals. We found no
CHEK2 variants in women with a family history of male
breast cancer, but there were only five individuals with such
a history in our entire sample. This finding is similar to those
of other recent studies that did not find an association
between 1100delC and risk for male breast cancer [24-
26]. Although the frequency of 1100delC carriers was
higher in cases (2.4%) and controls (3.2%) with a family
history of bilateral disease as compared with cases (0.7%)
and controls (0.3%) with no family history and cases
(1.8%) and controls (0) with only a family history of unilat-
eral disease, this was based on sparse data and family his-
tory of bilaterality contributed no insights beyond family
history overall.
After stratifying by family history, we did observe an ele-
vated frequency of 1100delC carriers among cases with a
first-degree family history (4.4%; P = 0.02). Although our
numbers are small, this frequency is similar to the frequen-
cies reported by others. Vahteristo and coworkers [6]
reported that, among 1035 breast cancer patients, 3.1% of
those with at least one affected first-degree or second-
degree relative were 1100delC carriers. Additionally, in
index cases with a family history of breast cancer, Meijers-
Heijboer and coworkers [5] observed that 3.0% (31/1036)
were 1100delC carriers.
Thus far, the most convincing evidence for an association
between the 1100delC variant and breast cancer risk is in
families who do not carry BRCA1/BRCA2 germline muta-
tions [5-7]. However, the 1100delC frequency in BRCA1/
BRCA2 mutation positive families did not differ significantly
from the frequency observed among controls [5,6]. In this
study we observed that four of 110 cases (3.6%) and none
of 33 controls who were known to be BRCA1 or BRCA2
negative carried the CHEK2  1100delC variant. The
number of women in the present study with a first-degree
family history of breast cancer who tested negative for
BRCA1/BRCA2 mutations (71 cases, 27 controls) does
not offer adequate power to detect differences in the fre-
quency of CHEK2 variants within this stratification.
The significance of the CHEK2 1100delC mutation in indi-
viduals with a family history of ovarian cancer is not as well
understood. Vahteristo and coworkers [6] found no associ-
ation between the 1100delC variant and ovarian cancer
family history among women with familial breast cancer (0/
40). However, Meijers-Heijboer and colleagues [5]
reported that 4.0% of index cases or 4.3% of all cases with
at least one family member with ovarian cancer carried the
Table 2
Association of CHEK2 variants with breast cancer risk
CHEK2 statusa Cases (n = 506) Controls (n = 459) ORb 95% CI
n % n %
1100del C
Noncarrier 499 98.8 456 99.6 1.0 Reference
Carrier 6 1.2 2 0.4 2.9 (0.6–14.6)
R145W
Noncarrier 505 99.8 459 100.0 1.0 Reference
C a r r i e r 1 0 . 2 0 ---
I175T
Noncarrier 504 99.6 455 99.1 1.0 Reference
Carrier 2 0.4 4 0.9 0.5 (0.1–2.6)
aAll carriers are heterozygous. bAdjusted for age at reference and reference year. CI, confidence interval; OR, odds ratio.Breast Cancer Research    Vol 6 No 6    Friedrichsen et al.
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1100delC variant (P = 0.016). This is compatible with the
frequency we observed (2/45 [4.4%]) among breast can-
cer cases with a family history of ovarian cancer. Although
the numbers are small, our data suggests that further inves-
tigation into the association between the CHEK2
1100delC mutation and ovarian cancer risk is warranted.
The results of our study should be assessed with regard to
its limits. Specifically, there are differences between tested
and untested women. Tested cases were more likely to be
alive, older, and have a less advanced stage of cancer than
untested cases. Thus, the generalizability of these results,
although from a population-based study, must be viewed
within that context. As noted earlier, the literature is diverse
in terms of its estimates of CHEK2 mutation frequency.
Although the overall sample size of our study was generous
(965 women), the frequency of the CHEK2 variants turned
out to be quite low. As a result, the study had somewhat
reduced power, particularly for assessing mutation fre-
quency according to various family history characteristics.
Conclusion
The population based, case–control study of young women
(age at diagnosis < 45 years) presented here does not
identify any of the 1100delC, R145W, and I175T variants
as major factors in breast cancer susceptibility in western
Washington. After stratification by family history character-
istics, an association with first-degree family history of
breast cancer and possibly family history of ovarian cancer
was observed. However, no particular relationship was
found with family history of bilateriality or family history of
male breast cancer. These results suggest that incorpora-
Table 3
Frequency of CHEK2 variants in cases and controls according to age and family history features
Characteristic All women 1100delC+ I175T+
Cases Controls Cases Controls Cases Controls
nn n % 95% CI n % 95% CI n %9 5 %  C I n %9 5 %  C I
Age (years)
< 30 10 16 0 0 0 0
30–34 52 64 0 0 0 1 1.6 0.04–8.4
35–39 156 140 1 0.6 0.02–3.5 1 0.7 0.02–3.9 1 0.6 0.02–3.5 0
40–44 288 239 5 1.7 0.6–4.0 1 0.4 0.01–2.3 1 0.3 0.009–1.9 3 1.3 0.3–3.6
Family History of breast cancera
None 280 294 2 0.7 0.09–2.6 1 0.3 0.009–1.9 1 0.4 0.009–2.0 3 1.0 0.2–3.0
First-degree 94 36 4 4.3 1.2–10.5 0 1 1.1 0.03–5.8 0
Second-degree only 120 115 0 1 0.9 0.02–4.7 0 1 0.9 0.02–4.7
Number of relatives with breast cancera
None 280 294 2 0.7 0.09–2.6 1 0.3 0.009–1.9 1 0.4 0.009–2.0 3 1.0 0.2–3.0
1 137 114 3 2.2 0.5–6.3 1 0.9 0.02–4.8 1 0.7 0.02–4.0 0
2 51 29 1 2.0 0.05–10.4 0 0 1 3.4 0.09–17.8
3+ 26 8 0 0 0 0
Family history of ovarian cancer
None 461 432 4 0.9 0.2–2.2 2 0.5 0.06–1.7 2 0.4 0.05–1.6 4 0.9 0.3–2.4
1st or 2nd degree 45 27 2 4.4 0.5–15.1 0 0 0
Family history of breast and/or ovarian cancera
No breast/no ovarian 258 278 2 0.8 0.09–2.8 1 0.4 0.009–2.0 1 0.4 0.01–2.1 3 1.1 0.2–3.1
No breast/yes ovarian 22 16 0 0 0 0
Yes breast/no ovarian 192 141 2 1.0 0.1–3.7 1 0.7 0.02–3.9 1 0.5 0.01–2.9 1 0.7 0.02–3.9
Yes breast/yes ovarian 22 10 2 9.1 1.1–29.2 0 0 0
aTwelve cases and 14 controls had missing information on their family history and are excluded. There were no CHEK2 variants in these women.Available online http://breast-cancer-research.com/content/6/6/R629
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tion of any CHEK2 variants into a breast cancer screening
program among Caucasian women in the US would be pre-
mat ure . Addi tio nal st udie s, parti cu larly of women  wi th  a
family history of breast cancer who do not carry mutations




The authors thank the study participants and area physicians for their 
generous contributions to this study, Kay Byron for programming assist-
ance, and Cecilia O'Brien for project coordination efforts. This research 
was supported in part by grants and contracts R01-CA-63697, R01-
CA-63705, N01-CP9567, R01-CA-59736, and N01-CN-67009 from 
the National Cancer Institute, FHCRC Interdisciplinary Training Grant 
CA80416 and K05CA90754-03 to EAO.
References
1. Shieh SY, Ahn J, Tamai K, Taya Y, Prives C: The human
homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phos-
phorylate p53 at multiple DNA damage-inducible sites. Genes
Dev 2000, 14:289-300.
2. Bartek J, Falck J, Lukas J: CHK2 kinase: a busy messenger. Nat
Rev Mol Cell Biol 2001, 2:877-886.
3. Seppala EH, Ikonen T, Mononen N, Autio V, Rokman A, Matikainen
MP, Tammela TL, Schleutker J: CHEK2 variants associate with
hereditary prostate cancer. Br J Cancer 2003, 89:1966-1970.
4. Dong X, Wang L, Taniguchi K, Wang X, Cunningham JM, McDon-
nell SK, Qian C, Marks AF, Slager SL, Peterson BJ, et al.: Muta-
tions in CHEK2 associated with prostate cancer risk. Am J
Hum Genet 2003, 72:270-280.
5. Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M,
de Snoo A, Oldenburg R, Hollestelle A, Houben M, et al.: Low-
penetrance susceptibility to breast cancer due to
CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2
mutations. Nat Genet 2002, 31:55-59.
6. Vahteristo P, Bartkova J, Eerola H, Syrjakoski K, Ojala S, Kilpivaara
O, Tamminen A, Kononen J, Aittomaki K, Heikkila P, et al.:  A
CHEK2 genetic variant contributing to a substantial fraction of
familial breast cancer. Am J Hum Genet 2002, 71:432-438.
7. Oldenburg RA, Kroeze-Jansema K, Kraan J, Morreau H, Klijn JG,
Hoogerbrugge N, Ligtenberg MJ, van Asperen CJ, Vasen HF, Mei-
jers C, et al.: The CHEK2*1100delC variant acts as a breast
cancer risk modifier in non-BRCA1/BRCA2 multiple-case
families. Cancer Res 2003, 63:8153-8157.
8. Offit K, Pierce H, Kirchhoff T, Kolachana P, Rapaport B, Gregersen
P, Johnson S, Yossepowitch O, Huang H, Satagopan J, et al.: Fre-
quency of CHEK2*1100delC in New York breast cancer cases
and controls. BMC Med Genet 2003, 4:1.
9. Allinen M, Huusko P, Mantyniemi S, Launonen V, Winqvist R:
Mutation analysis of the CHK2 gene in families with hereditary
breast cancer. Br J Cancer 2001, 85:209-212.
10. Schutte M, Seal S, Barfoot R, Meijers-Heijboer H, Wasielewski M,
Evans DG, Eccles D, Meijers C, Lohman F, Klijn J, et al.: Variants
in CHEK2 other than 1100delC do not make a major contribu-
tion to breast cancer susceptibility. Am J Hum Genet 2003,
72:1023-1028.
11. Osorio A, Rodriguez-Lopez R, Diez O, de la Hoya M, Ignacio Mar-
tinez J, Vega A, Esteban-Cardenosa E, Alonso C, Caldes T, Beni-
tez J: The breast cancer low-penetrance allele 1100delC in the
CHEK2 gene is not present in Spanish familial breast cancer
population. Int J Cancer 2004, 108:54-56.
12. Rajkumar T, Soumittra N, Nancy NK, Swaminathan R, Sridevi V,
Shanta V: BRCA1, BRCA2 and CHEK2 (1100 del C) germline
mutations in hereditary breast and ovarian cancer families in
South India. Asian Pac J Cancer Prev 2003, 4:203-208.
13. Brinton LA, Daling JR, Liff JM, Schoenberg JB, Malone KE, Stan-
ford JL, Coates RJ, Gammon MD, Hanson L, Hoover RN: Oral con-
traceptives and breast cancer risk among younger women. J
Natl Cancer Inst 1995, 87:827-835.
14. Daling JR, Malone KE, Voigt LF, White E, Weiss NS: Risk of
breast cancer among young women: relationship to induced
abortion. J Natl Cancer Inst 1994, 86:1584-1592.
15. Waksberg J: Sample methods for random digit dialing. J Am
Stat Soc 1978, 73:40-46.
16. Vahteristo P, Tamminen A, Karvinen P, Eerola H, Eklund C, Aalto-
nen LA, Blomqvist C, Aittomaki K, Nevanlinna H: p53, CHK2, and
CHK1 genes in Finnish families with Li-Fraumeni syndrome:
further evidence of CHK2 in inherited cancer predisposition.
Cancer Res 2001, 61:5718-5722.
17. Breslow NE, Day NE: Statistical Methods in Cancer Research.
The Analysis of Case–control Studies Issue I Lyon: IARC Scien-
tific Publications; 1980. 
18. Malone KE, Daling JR, Thompson JD, O'Brien CA, Francisco LV,
Ostrander EA: BRCA1 mutations and breast cancer in the gen-
eral population: analyses in women before age 35 years and in
women before age 45 years with first-degree family history.
JAMA 1998, 279:922-929.
19. Malone KE, Daling JR, Neal C, Suter NM, O'Brien C, Cushing-Hau-
gen K, Jonasdottir TJ, Thompson JD, Ostrander EA: Frequency of
BRCA1/BRCA2 mutations in a population-based sample of
young breast carcinoma cases. Cancer 2000, 88:1393-1402.
20. Wu X, Webster SR, Chen J: Characterization of tumor-associ-
ated Chk2 mutations. J Biol Chem 2001, 276:2971-2974.
21. Li J, Williams BL, Haire LF, Goldberg M, Wilker E, Durocher D,
Yaffe MB, Jackson SP, Smerdon SJ: Structural and functional
versatility of the FHA domain in DNA-damage signaling by the
tumor suppressor kinase Chk2. Mol Cell 2002, 9:1045-1054.
22. Falck J, Mailand N, Syljuasen RG, Bartek J, Lukas J: The ATM-
Chk2-Cdc25A checkpoint pathway guards against radioresist-
ant DNA synthesis. Nature 2001, 410:842-847.
23. Broeks A, de Witte L, Nooijen A, Huseinovic A, Klijn JG, van Leeu-
wen FE, Russell NS, van't Veer LJ: Excess risk for contralateral
breast cancer in CHEK2*1100delC germline mutation carriers.
Breast Cancer Res Treat 2004, 83:91-93.
24. Syrjakoski K, Kuukasjarvi T, Auvinen A, Kallioniemi OP: CHEK2
1100delC is not a risk factor for male breast cancer population.
Int J Cancer 2004, 108:475-476.
25. Neuhausen S, Dunning A, Steele L, Yakumo K, Hoffman M, Szabo
C, Tee L, Baines C, Pharoah P, Goldgar D, Easton D: Role of
CHEK2*1100delC in unselected series of non-BRCA1/2 male
breast cancers. Int J Cancer 2004, 108:477-478.
26. Ohayon T, Gal I, Baruch RG, Szabo C, Friedman E:
CHEK2*1100delC and male breast cancer risk in Israel. Int J
Cancer 2004, 108:479-480.